Početna › Burkittov limfom › Washington
Kliničke studije za Burkittov limfom u državi Washington
11 studija za Burkittov limfom traži sudionike na lokacijama u državi Washington.
Gradovi u državi Washington
Službeni tekst studije (engleski)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
U tijeku regrutacijaFaza 2
366 Days – 46 Years · Oba spola · Ažurirano 2. lis 2026. · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
U tijeku regrutacijaFaza 2
365 Days · Oba spola · Ažurirano 25. ruj 2026. · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- i još 1
U tijeku regrutacijaFaza 2
Od 1 do 30 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
U tijeku regrutacijaFaza 3
365 Days – 25 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT06710418Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
U tijeku regrutacijaFaza 2Zdravi dobrovoljci dobrodošli
6 Months · Oba spola · Ažurirano 29. svi 2026. · NCT04195633Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 23. tra 2026. · NCT07097363Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. velj 2026. · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Fred Hutchinson Cancer Research Center, Seattle
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 5. stu 2025. · NCT04260022Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 15. stu 2024. · NCT06034275Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.